47 results
PX14A6G
Boston Common Asset Management, LLC
18 May 23
Letter to shareholders
4:46pm
in corporate electoral spending
Misaligned or non-transparent funding creates reputational risk that can harm shareholder value.
The SEC has determined … not to contribute to an organization.
Misaligned or non-transparent funding creates reputational risk that can harm shareholder value
Contributions to third
PX14A6G
Oxfam America, Inc.
21 Apr 23
Letter to shareholders
7:39pm
funded treatment in 2022, making it Merck’s third highest revenue product.5 However, the company has not been transparent about whether and how public … Merck’s license excludes, including developing middle-income countries, are subject to the company’s opaque and non-transparent tiered pricing strategy
PX14A6G
MRK
Merck & Co Inc
19 Apr 23
Letter to shareholders
4:04pm
However, the company has not been transparent about whether and how public investment in this medicine has factored into the company’s access … , are subject to the company’s opaque and non-transparent tiered pricing strategy.10 Tiered pricing often results in unaffordable prices for medicines.11
PX14A6G
a67jl4pdm h79wtm
13 May 22
Letter to shareholders
2:32pm
424B3
flb s4psb
25 Jun 09
Prospectus supplement
12:00am